Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2016 Dec 3

PMID 27909986

Citations 48

Authors

Kimberley S Samkoe

Jason R Gunn

Kayla Marra

Sally M Hull

Karen L Moodie

Joachim Feldwisch

Theresa V Strong

Daniel R Draney

P Jack Hoopes

David W Roberts

Keith Paulsen

Brian W Pogue

Affiliations

Soon will be listed here.

Abstract

Purpose: ABY-029, a synthetic Affibody peptide, Z03115-Cys, labeled with a near-infrared fluorophore, IRDye® 800CW, targeting epidermal growth factor receptor (EGFR) has been produced under good manufacturing practices for a US Food and Drug Administration-approved first-in-use human study during surgical resection of glioma, as well as other tumors. Here, the pharmacology, phototoxicity, receptor activity, and biodistribution studies of ABY-029 were completed in rats, prior to the intended human use.

Procedures: Male and female Sprague Dawley rats were administered a single intravenous dose of varying concentrations (0, 245, 2449, and 24,490 μg/kg corresponding to 10×, 100×, and 1000× an equivalent human microdose level) of ABY-029 and observed for up to 14 days. Histopathological assessment of organs and tissues, clinical chemistry, and hematology were performed. In addition, pharmacokinetic clearance and biodistribution of ABY-029 were studied in subgroups of the animals. Phototoxicity and ABY-029 binding to human and rat EGFR were assessed in cell culture and on immobilized receptors, respectively.

Results: Histopathological assessment and hematological and clinical chemistry analysis demonstrated that single-dose ABY-029 produced no pathological evidence of toxicity at any dose level. No phototoxicity was observed in EGFR-positive and EGFR-negative glioma cell lines. Binding strength and pharmacokinetics of the anti-EGFR Affibody molecules were retained after labeling with the dye.

Conclusion: Based on the successful safety profile of ABY-029, the 1000× human microdose 24.5 mg/kg was identified as the no observed adverse effect level following intravenous administration. Conserved binding strength and no observed light toxicity also demonstrated ABY-029 safety for human use.

Citing Articles

Two-color fluorescence-guided surgery for head and neck cancer resections.

Szafran D, Shams N, Montano A, Rizvi S, Alani A, Samkoe K J Biomed Opt. 2024; 30(Suppl 1):S13707.

PMID: 39473456 PMC: 11519810. DOI: 10.1117/1.JBO.30.S1.S13707.

In Vivo Labeling and Detection of Circulating Tumor Cells in Mice Using OTL38.

Pace J, Lee J, Srinivasarao M, Kallepu S, Low P, Niedre M Mol Imaging Biol. 2024; 26(4):603-615.

PMID: 38594545 PMC: 11281960. DOI: 10.1007/s11307-024-01914-0.

Quantitative pharmacokinetic and biodistribution studies for fluorescent imaging agents.

Feng Y, Pannem S, Hodge S, Rounds C, Tichauer K, Paulsen K Biomed Opt Express. 2024; 15(3):1861-1877.

PMID: 38495714 PMC: 10942698. DOI: 10.1364/BOE.504878.

Quantifying Imaging Agent Binding and Dissociation in 3-D Cancer Spheroid Tissue Culture Using Paired-Agent Principles.

Li C, Rounds C, Torres V, He Y, Xu X, Papavasiliou G Ann Biomed Eng. 2024; 52(6):1625-1637.

PMID: 38409434 PMC: 10174639. DOI: 10.1007/s10439-024-03476-2.

Subsurface fluorescence time-of-flight imaging using a large-format single-photon avalanche diode sensor for tumor depth assessment.

Petusseau A, Streeter S, Ulku A, Feng Y, Samkoe K, Bruschini C J Biomed Opt. 2024; 29(1):016004.

PMID: 38235320 PMC: 10794045. DOI: 10.1117/1.JBO.29.1.016004.

References

Zimmermann M, Zouhair A, Azria D, Ozsahin M . The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol. 2006; 1:11. PMC: 1524965. DOI: 10.1186/1748-717X-1-11. View

Heath C, Deep N, Sweeny L, Zinn K, Rosenthal E . Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model. Ann Surg Oncol. 2012; 19(12):3879-87. PMC: 3595117. DOI: 10.1245/s10434-012-2435-y. View

Miller J, Schmidt-Erfurth U, Sickenberg M, Pournaras C, Laqua H, Barbazetto I . Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999; 117(9):1161-73. DOI: 10.1001/archopht.117.9.1161. View

Feldwisch J, Tolmachev V . Engineering of affibody molecules for therapy and diagnostics. Methods Mol Biol. 2012; 899:103-26. DOI: 10.1007/978-1-61779-921-1_7. View

Tolmachev V, Orlova A, Nilsson F, Feldwisch J, Wennborg A, Abrahmsen L . Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther. 2007; 7(4):555-68. DOI: 10.1517/14712598.7.4.555. View

Reagan-Shaw S, Nihal M, Ahmad N . Dose translation from animal to human studies revisited. FASEB J. 2007; 22(3):659-61. DOI: 10.1096/fj.07-9574LSF. View

Souza A, Marra K, Gunn J, Samkoe K, Hoopes P, Feldwisch J . Fluorescent Affibody Molecule Administered In Vivo at a Microdose Level Labels EGFR Expressing Glioma Tumor Regions. Mol Imaging Biol. 2016; 19(1):41-48. PMC: 5209393. DOI: 10.1007/s11307-016-0980-7. View

Schmidt-Erfurth U, Miller J, Sickenberg M, Laqua H, Barbazetto I, Gragoudas E . Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 1999; 117(9):1177-87. DOI: 10.1001/archopht.117.9.1177. View

Baum R, Prasad V, Muller D, Schuchardt C, Orlova A, Wennborg A . Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med. 2010; 51(6):892-7. DOI: 10.2967/jnumed.109.073239. View

10.

Stummer W, Pichlmeier U, Meinel T, Wiestler O, Zanella F, Reulen H . Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7(5):392-401. DOI: 10.1016/S1470-2045(06)70665-9. View

11.

Stummer W, Stepp H, Moller G, Ehrhardt A, Leonhard M, Reulen H . Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir (Wien). 1998; 140(10):995-1000. DOI: 10.1007/s007010050206. View

12.

Verbeek F, van der Vorst J, Tummers Q, Boonstra M, de Rooij K, Lowik C . Near-infrared fluorescence imaging of both colorectal cancer and ureters using a low-dose integrin targeted probe. Ann Surg Oncol. 2014; 21 Suppl 4:S528-37. PMC: 4128907. DOI: 10.1245/s10434-014-3524-x. View

13.

Marshall M, Draney D, Sevick-Muraca E, Olive D . Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats. Mol Imaging Biol. 2010; 12(6):583-94. PMC: 2978892. DOI: 10.1007/s11307-010-0317-x. View

14.

Valdes P, Kim A, Brantsch M, Niu C, Moses Z, Tosteson T . δ-aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas: the need for quantitative fluorescence-guided resection to identify regions of increasing malignancy. Neuro Oncol. 2011; 13(8):846-56. PMC: 3145475. DOI: 10.1093/neuonc/nor086. View

15.

Gleysteen J, Newman J, Chhieng D, Frost A, Zinn K, Rosenthal E . Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck. 2008; 30(6):782-9. PMC: 4402971. DOI: 10.1002/hed.20782. View

16.

Sandstrom M, Lindskog K, Velikyan I, Wennborg A, Feldwisch J, Sandberg D . Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients. J Nucl Med. 2016; 57(6):867-71. DOI: 10.2967/jnumed.115.169342. View

17.

Friedman M, Orlova A, Johansson E, Eriksson T, Hoiden-Guthenberg I, Tolmachev V . Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol. 2008; 376(5):1388-402. DOI: 10.1016/j.jmb.2007.12.060. View

18.

Day K, Sweeny L, Kulbersh B, Zinn K, Rosenthal E . Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol. 2013; 15(6):722-9. PMC: 3951369. DOI: 10.1007/s11307-013-0652-9. View

19.

Stummer W, Reulen H, Meinel T, Pichlmeier U, Schumacher W, Tonn J . Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008; 62(3):564-76. DOI: 10.1227/01.neu.0000317304.31579.17. View

20.

van Scheltinga A, van Dam G, Nagengast W, Ntziachristos V, Hollema H, Herek J . Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med. 2011; 52(11):1778-85. DOI: 10.2967/jnumed.111.092833. View